Results 21 to 30 of about 8,552 (153)
Myostatin regulates the production of fibroblast growth factor 23 (FGF23) in UMR106 osteoblast-like cells. [PDF]
Pflugers Arch, 2021 AbstractMyostatin is a signaling molecule produced by skeletal muscle cells (myokine) that inhibits muscle hypertrophy and has further paracrine and endocrine effects in other organs including bone. Myostatin binds to activin receptor type 2B which forms a complex with transforming growth factor-β type I receptor (TGF-βRI) and induces intracellular ...
Ewendt F, Feger M, Föller M.
europepmc +6 more sources
High fat diet induces gastric production of fibroblast growth factor 23 (FGF23). [PDF]
Int J Obes (Lond)Abstract Background A high fat diet (HFD) leads to lesions of the gastric epithelium and causes a proinflammatory environment. Fibroblast growth factor 23 (FGF23), a bone hormone, regulates renal phosphate and vitamin D metabolism. Under pathophysiological conditions production of FGF23 is stimulated.
Widmayer P +4 more
europepmc +3 more sources
A comparative transcriptome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. [PDF]
PLoS ONE, 2012 Elevations of circulating Fibroblast growth factor 23 (FGF23) are associated with adverse cardiovascular outcomes and progression of renal failure in chronic kidney disease (CKD).
Bing Dai +7 more
doaj +1 more source
Fibroblast Growth Factor 23 (FGF23) and Disorders of Phosphate Metabolism [PDF]
International Journal of Pediatric Endocrinology, 2009 Derangements in serum phosphate level result in rickets/osteomalacia or ectopic calcification indicating that healthy people without these abnormalities maintain serum phosphate within certain ranges. These results indicate that there must be a regulatory mechanism of serum phosphate level. Fibroblast growth factor 23 (FGF23) was identified as the last
Saito, Tasuku, Fukumoto, Seiji
openaire +2 more sources
Tumor-induced osteomalacia: Easing the diagnosis with fibroblast growth factor 23
APIK Journal of Internal Medicine, 2022 Tumor-induced osteomalacia (TIO), is a rare paraneoplastic syndrome resulting in bone pain, muscle weakness, and recurrent fractures. Hypophosphatemia, hyperphosphaturia, low 1, 25 dihydroxyVitamin D, and normal serum calcium are noted.
Mala Dharmalingam, Lohit Kumbar
doaj +1 more source
Frontiers in Pediatrics, 2021 Cardiovascular diseases (CVD) are a hallmark in pediatric patients with chronic kidney disease (CKD) contributing to an enhanced risk of all-cause and CV morbidity and mortality in these patients.
Andrea Grund +6 more
doaj +1 more source
Levels of Circulating Fibroblast Growth Factor 23 (FGF23) and Prognosis in Cancer Patients with Bone Metastases. [PDF]
Int J Mol Sci, 2019 The fibroblast growth factor (FGF) signaling pathway plays a key role in tumorigenesis and is recognized as a potential therapeutic target. In this study, the authors aimed to assess the impact of serum FGF23 levels in the prognosis of patients with cancer and bone metastases from solid tumors.
Mansinho A +12 more
europepmc +5 more sources
Does fibroblast growth factor 23 correlates with volume status in hemodialysis patients? [PDF]
Journal of Nephropathology, 2019 Introduction: Volume overload is a known risk factor for cardiovascular disease and stroke in hemodialysis patients. The use of fibroblast growth factor 23 (FGF23) as a volume overload marker has been validated in multiple studies.
Farzanehsadat Minoo +2 more
doaj +1 more source
Inhibition of fibroblast growth factor 23 (FGF23) signaling rescues renal anemia.
FASEB J, 2018 Severe anemia and iron deficiency are common complications in chronic kidney disease. The cause of renal anemia is multifactorial and includes decreased erythropoietin (Epo) production, iron deficiency, and inflammation, and it is currently treated with injections of synthetic Epo.
Agoro R +8 more
europepmc +4 more sources
The Complexity of FGF23 Effects on Cardiomyocytes in Normal and Uremic Milieu
Cells, 2021 Fibroblast growth factor-23 (FGF23) appears to be one of the most promising biomarkers and predictors of cardiovascular risk in patients with heart disease and normal kidney function, but moreover in those with chronic kidney disease (CKD).
Andreja Figurek +2 more
doaj +1 more source